AI-Powered Colon Cancer Diagnosis: Panakeia’s PANProfiler Colon Shows Promise in Real-World Study
Cambridge, UK (January 23, 2025) – Panakeia, a leading innovator in AI-driven diagnostics, is generating significant buzz at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The company’s groundbreaking PANProfiler Colon software, designed to rapidly identify Microsatellite Instability (MSI) and Mismatch Repair Deficiency (dMMR) directly from routine tissue samples, has demonstrated impressive accuracy in a real-world, multi-site validation study.
MSI and dMMR status are crucial factors in determining personalized treatment strategies for colorectal cancer patients. Knowing this information allows clinicians to identify patients who may benefit from targeted therapies, like immune checkpoint inhibitors, leading to improved outcomes.
PANProfiler Colon leverages advanced AI algorithms to analyze Hematoxylin and Eosin (H&E)-stained tissue images, providing rapid and reliable MSI/dMMR detection. In a study involving 3178 colorectal cancer patient samples, the software achieved a remarkable 92.69% positive agreement and 94.05% negative agreement for MSI/dMMR detection. These results, presented at ASCO, underscore the potential of PANProfiler Colon to revolutionize routine clinical practice.
"These findings are incredibly encouraging," states Pahini Pandya, Founder and CEO of Panakeia. "PANProfiler Colon empowers pathologists and clinicians to make informed decisions about treatment plans quickly and efficiently, ultimately benefiting patients."
Currently, PANProfiler Colon holds UKCA-marking for use in the UK. While the broader PANProfiler platform, which analyzes biomarkers across over 30 cancer types, is currently available for Research Use Only (RUO), Panakeia’s commitment to advancing pathology through AI-driven technologies is evident.
Panakeia’s innovative approach holds immense promise for improving cancer diagnosis and treatment. Their commitment to developing accessible and reliable AI-powered tools has positioned them as a leader in the field, paving the way for a future where personalized medicine becomes the standard of care.